Change in plasma immunoreactive atrial natriuretic peptide during sequential ultrafiltration and haemodialysis

Wilkins, Martin R.; Wood, J.; Adu, D.; Lote, Christopher J.; Kendall, M. J.; Michael, J.

doi:10.1042/cs0710157

Cited by 80 publications

(44 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating AP is thought to have a role in regulating intravascular volume. Consistent with this, plasma levels rise with intravascular volume expansion (3) and fall with volume depletion (4). Moreover, pretreatment of rats with monoclonal antibody raised against AP markedly attenuates the natriuretic response of these animals to acute volume expansion (5).…”

Section: Introductionsupporting

confidence: 50%

Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation.

Wilkins

Settle²,

Needleman³

1990

J. Clin. Invest.

View full text Add to dashboard Cite

To investigate the relationship between AP, cyclic GMP, and sodium excretion, we studied the effect of a cyclic GMP phosphodiesterase inhibitor (M + B22948) on the natriuretic response to (a) an infusion of AP (103-126) and (b) acute volume expansion in rats. The phosphodiesterase inhibitor markedly potentiated the effect of low-dose AP infusions on urinary sodium and cyclic GMP excretion without potentiating the fall in blood pressure. Acute volume expansion (1% body wt) led to small but significant (P < 0.01) rises in plasma AP and urinary cyclic GMP levels. Pretreatment with the phosphodiesterase inhibitor enhanced the natriuretic and cyclic GMP response to volume loading, an effect that was attenuated by administration of a monoclonal antibody directed against AP. These data indicate that cyclic GMP mediates the natriuretic activity of AP and AP and cyclic GMP play active roles in the natriuresis of acute volume expansion. Moreover, pharmacological manipulation of cyclic GMP levels may prove a useful therapeutic strategy for facilitating the natriuretic but not the hypotensive effects of

show abstract

Section: Introductionsupporting

confidence: 50%

Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation.

Wilkins

Settle²,

Needleman³

1990

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…7 -9 Further-more, ANF is markedly elevated in end-stage renal failure, and the half-life of exogenous peptide administered to anephric rats is double that found in normal animals. 10 -" Hence, we have examined plasma ANF concentrations and their relationship to arterial pressure, age, LVH, and renal function in normotensive and hypertensive subjects.…”

mentioning

confidence: 99%

Correlates of plasma atrial natriuretic factor in health and hypertension.

et al. 1987

View full text Add to dashboard Cite

Plasma concentrations of atrial natriuretic factor (ANF) were compared in normoten-sive subjects and subjects with untreated, uncomplicated essential hypertension (n = 2l pairs) matched for age, sex, and race. Plasma peptide values were slightly greater (45 ± 3 vs 36 ± 3 pg/ml; p<0.05) in the hypertensive group. On univariate analysis, age (r=0.52, n = 47, p<0.001) and creatinine clearance (r =-0.30, n = 47, p<0.05) were significantly related to plasma ANF concentrations , but arterial pressure was not (r = 0.14, n = 47), in an extended group of normal subjects. In contrast, plasma ANF values were related to arterial pressure in both an extended group of subjects with untreated essential hypertension (r = 0.54, n = 38, p<0.001) and in our total heterogeneous pool of hypertensive patients (r = 0.46, n = 79, p<0.001), but weak positive associations with age and inverse relationships with creatinine clearance were not statistically significant in either hypertensive group. Similar weak inverse relationships between plasma ANF values and renin-angiotensin-aldo-sterone system activity were found in both normal and hypertensive subjects. Plasma ANF concentration was related to electrocardiographic scores for left ventricular hypertrophy and to radiological cardiothoracic ratio in subjects with untreated essential hypertension (r = 0.53, n = 34, p<0.01 and r = 0.35, n = 32, p<0.05, respectively) and for all hypertensive subjects combined (r = 0.35, n = 59, p<0.02 for cardiothoracic ratio and r = 0. 4 7 , n = 69, p<0.001 for hypertrophy scores). Seventy percent of subjects with left ventricular hypertrophy had plasma ANF values beyond the normal range for our laboratory. Comparison of hypertensive subjects with and without hypertrophy, closely matched for age and arterial pressure (n = 13 pairs), revealed clearly elevated values of plasma ANF in the hypertrophy group (133 ± 24 vs 46 ± 5 pg/ml; p<0.01). (Hypertension 10: 570-576, 1987) KEY WORDS • atrial natriuretic factor • hypertension • arterial pressure • left ventricular hypertrophy • renal function • age • renin-angiotensin-aldosterone system P LASMA atrial natriuretic factor (ANF) concentrations have been reported as elevated in essential hypertension, and a positive relationship between arterial pressure and ANF values has been described. '~ 3 However, overlap of ANF levels in hypertensive and normotensive subjects appears considerable , and other workers have found no difference between these groups. 4 To clarify and perhaps reconcile these conflicting reports, we have looked at other factors, aside from arterial pressure, that may help dictate plasma ANF concentrations in hypertension. These include age, left ventricular hypertrophy (LVH), and renal function. Age and plasma ANF values are positively related, at least in normotensive subjects. 1-5 Ventricular hyper-trophy is associated with decreased ventricular compliance and consequent elevations in mean atrial pressures. Atrial distention remains the primary candidate as the main stimulus for ANF secretion. P...

show abstract

“…nitric oxide inhibitors, endothelins, neuropeptide Y, bradykinin), or that HD time altered the BP responsiveness to neurohormones or sympathetic activity. ANP is secreted in response to atrial stretch and is an indicator of ECF volume in ESRD [18]. ANP was similar after both treatments, which suggests that ECF volume was seldom normalized by either form of dialysis.…”

Section: Discussionmentioning

confidence: 92%

A Comparative Study of Blood Pressure Control with Short In-Center versus Long Home Hemodialysis

McGregor¹,

Buttimore²,

Lynn³

et al. 2001

Blood Purif

View full text Add to dashboard Cite

We conducted a randomized crossover trial to establish, within patients, whether long-slow hemodialysis (HD) was associated with better blood pressure (BP) control than standard HD. Nine home HD patients, not on antihypertensive drugs, were dialyzed to the same eKt/V_urea and target weights for 6–8 h (LD) at home and for 3.5–4.5 h (SD) in the dialysis center 3 times weekly in randomized sequence, with each phase lasting 8 weeks. Ambulatory BP, bioimpedance, neurohormones and autonomic function were measured in each phase. Pre- and postdialysis systolic, ambulatory systolic and diastolic BP were all higher with SD than with LD and intradialysis hypotension was more common. Weight, ECF volume and neurohormones did not differ between treatments. Muscle sympathetic activity was increased in both phases and cardiac sympathetic activity tended higher during SD. These findings suggest that additional factors to ECF volume may contribute to the superior BP control produced by long-slow HD.

show abstract

Change in plasma immunoreactive atrial natriuretic peptide during sequential ultrafiltration and haemodialysis

Cited by 80 publications

References 0 publications

Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation.

Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3',5'-cyclic monophosphate degradation.

Correlates of plasma atrial natriuretic factor in health and hypertension.

A Comparative Study of Blood Pressure Control with Short In-Center versus Long Home Hemodialysis

Contact Info

Product

Resources

About